Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 2.516 EUR -1.33% Market Closed
Market Cap: 428.2m EUR

Net Margin
Valneva SE

-11.6%
Current
-23%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-11.6%
=
Net Income
-30.7m
/
Revenue
264.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
FR
Valneva SE
PAR:VLA
408.6m EUR
-12%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
339.9B USD
7%
US
Amgen Inc
NASDAQ:AMGN
158.8B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
136.5B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.5B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
116.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.4B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41B USD
-11%

Valneva SE
Glance View

Market Cap
408.6m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-11.6%
=
Net Income
-30.7m
/
Revenue
264.6m
What is the Net Margin of Valneva SE?

Based on Valneva SE's most recent financial statements, the company has Net Margin of -11.6%.

Back to Top